Arkadios Wealth Advisors grew its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 100.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,075 shares of the company's stock after buying an additional 5,541 shares during the period. Arkadios Wealth Advisors' holdings in Zoetis were worth $1,823,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Navigoe LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $30,000. Cornerstone Planning Group LLC grew its stake in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after purchasing an additional 120 shares during the period. Sound Income Strategies LLC grew its stake in shares of Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares during the period. Finally, Bfsg LLC grew its position in Zoetis by 614.6% during the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after acquiring an additional 252 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.
Zoetis Price Performance
NYSE:ZTS opened at $145.76 on Friday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The stock's 50-day simple moving average is $158.82 and its 200 day simple moving average is $160.58. The company has a market cap of $64.89 billion, a P/E ratio of 26.17, a P/E/G ratio of 2.47 and a beta of 0.91. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.
Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter last year, the company posted $1.38 earnings per share. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.
Zoetis Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.
Insider Activity
In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
A number of research firms recently commented on ZTS. UBS Group decreased their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Piper Sandler increased their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $204.63.
Read Our Latest Research Report on ZTS
Zoetis Company Profile
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.